2-氨基-3-氰基-4-苯基吡咯 | 54153-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 2-氨基-3-氰基-4-苯基吡咯
• 英文名称: 2-amino-3-cyano-4-phenylpyrrole
• 英文别名: 2-amino-4-phenyl-1H-pyrrole-3-carbonitrile；2-amino-4-phenylpyrrolyl-3-carbonitrile；2-Amino-3-cyan-4-phenyl-pyrrol
• CAS: 54153-51-4
• 化学式: C₁₁H₉N₃
• 分子量: 183.213
• InChiKey: XYEJDFIDVKWWTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氨基-3-氰基-4-苯基吡咯 在 对甲苯磺酸 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.25h， 生成 4-N-(4-methylphenyl)amino-5-phenylpyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  Adenosine Kinase Inhibitors. 2. Synthesis, Enzyme Inhibition, and Antiseizure Activity of Diaryltubercidin Analogues

  摘要：

  In the preceding article (Ugarkar et al. J. Med. Chem. 2000, 43) we reported that analogues of tubercidin are potent adenosine kinase (AK) inhibitors with antiseizure activity in the rat maximum electroshock (MES) model. Despite the discovery of several highly potent AK inhibitors (AKIs), e.g., 5'-amino-5'-deoxy-5-iodotubercidin (1c) (IC50 = 0.0006 mu M), no compounds were identified that exhibited a safety, efficacy, and side effect profile suitable for further development. In this article, we demonstrate that substitution of the tubercidin molecule with aromatic rings at the N4- and the C5-positions not only retains AKI potency but also improves in vivo activity. Synthesis of such compounds entailed transformation of 4-arylanlino-5-iodotubercidin analogues to their corresponding 5-aryl derivatives via the Suzuki reaction. Alternatively, 4-N-suylamino-5-arylpyrrolo[2,3-d]pyrimdine bases were constructed and then glycosylated with appropriately protected alpha-ribofuranosyl chlorides using a phase-transfer catalyst. Several compounds exhibited potent activity in the rat MES seizure assay with ED(50)s less than or equal to 2.0 mg/kg, ip, and showed relatively mild side effects.

  DOI：

  10.1021/jm0000259
• 作为产物：
  描述：

  2-氨基苯乙酮 在 盐酸 、 sodium hydroxide 、 sodium acetate 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 0.25h， 生成 2-氨基-3-氰基-4-苯基吡咯
  参考文献：
  名称：

  Bayomi; Al-Obaid; Jado, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 1, p. 47 - 52

  摘要：

  DOI：

文献信息

• Orally active adenosine kinase inhibitors
  申请人：Metabasis Therapeutics, Inc.

  公开号：US05763597A1

  公开（公告）日：1998-06-09

  This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to orally active, substituted 5-aryl pyrrolo\x9b2,3-d! pyrimidine and 3-aryl pyrazolo\x9b3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

  这项发明涉及腺苷激酶抑制剂和核苷类似物，具体涉及口服活性的取代5-芳基吡咯并[2,3-d]嘧啶和3-芳基吡唑并[3,4-d]嘧啶核苷类似物，其作为腺苷激酶抑制剂的活性。该发明还涉及这些和其他腺苷激酶抑制剂的制备和使用，用于治疗心血管和脑血管疾病、炎症和其他可以通过增加腺苷局部浓度来调节的疾病。
• COMPOUND OR ITS TAUTOMER, METAL COMPLEX COMPOUND, COLORED PHOTOSENSITIVE CURING COMPOSITION, COLOR FILTER, AND PRODUCTION
  申请人：MIZUKAWA Yuki

  公开号：US20120238752A1

  公开（公告）日：2012-09-20

  Provided is a colored photosensitive curing composition useful for color filters in primary colors, including blue, green, and red, having a high molar absorption coefficient and allowing a reduction in film thickness and superior color purity and fastness. A colored photosensitive curing composition, comprising, as its colorant, a dipyrromethene-based metal complex compound obtained from a metal or metal compound and a dipyrromethene-based compound represented by the following Formula (I): wherein in Formula (I), R 1 to R 6 each independently represent a hydrogen atom or a substituent group; and R 7 represents a hydrogen or halogen atom, or an alkyl, aryl or heterocyclic group.

  提供的是一种有用于原色彩色滤光片的彩色光敏固化组合物，包括蓝色、绿色和红色，具有高摩尔吸收系数，可减少薄膜厚度，具有优越的颜色纯度和牢固度。 一种彩色光敏固化组合物，包括作为其着色剂的从金属或金属化合物获得的基于二吡咯甲烷的金属配合物化合物和由以下式（I）表示的基于二吡咯甲烷的化合物，其中在式（I）中，R1至R6各自独立地表示氢原子或取代基；R7表示氢或卤素原子，或烷基、芳基或杂环基。
• Synthesis of 8-cyano-1,4-dihydro-4-oxopyrrolo[1,2-a]pyrimidine-3-carboxylic acids as potential antimicrobial agents
  作者：Ghassan M. Abdalla、J. Walter Sowell

  DOI：10.1002/jhet.5570240201

  日期：1987.3

  The preparation of a variety of 8-cyano-1,4-dihydro-7-phenyl-4-oxopyrrolo[1,2-a]pyrimidine-3-carboxylicacids and 8-cyano-1,4-dihydro-7-p-fluorophenyl-4-oxopyrrolo[1,2-a]pyrimidine-3-carboxylic acids is described.

  各种8-氰基-1,4-二氢-7-苯基-4-氧代吡咯的制备[1,2一]嘧啶-3- carboxylicacids和8-氰基-1,4-二氢-7- p -描述了氟苯基-4-氧代吡咯并[1,2- a ]嘧啶-3-羧酸。
• [EN] MAP4K4 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K4
  申请人：IMPERIAL INNOVATIONS LTD

  公开号：WO2019073253A1

  公开（公告）日：2019-04-18

  This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).

  这项发明涉及含有吡咯吡嘧啶的化合物，这些化合物可能作为丝裂原活化蛋白激酶激酶激酶激酶-4（MAP4K4）的抑制剂而有用。该发明还涉及利用这些含有吡咯吡嘧啶的化合物，例如在治疗方法中的使用。还提供了生产本发明化合物的方法以及它们的使用方法。具体而言，本发明涉及式（I）的化合物。
• Water soluble adenosine kinase inhibitors
  申请人：Gensia Inc.

  公开号：US05726302A1

  公开（公告）日：1998-03-10

  This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to water soluble, aryl substituted 4-amino pyrrolo\x9b2,3-d! pyrimidine and pyrazolo\x9b3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

  这项发明涉及腺苷激酶抑制剂和核苷类似物，具体涉及水溶性、芳基取代的4-氨基吡咯[2,3-d]嘧啶和吡唑[3,4-d]嘧啶核苷类似物，其具有作为腺苷激酶抑制剂的活性。该发明还涉及这些腺苷激酶抑制剂的制备和用途，用于治疗心血管和脑血管疾病、炎症以及其他可以通过增加腺苷局部浓度来调节的疾病。